Cargando…

Combination Therapies for Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) is considered a highly prevalent disease associated with various co-morbidities that lead to socioeconomic burden. Despite large-scale investigation, no pharmacological treatment has been approved specifically for NAFLD to date. Lifestyle modifications and di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makri, Evangelia S., Makri, Eleftheria, Polyzos, Stergios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322793/ https://www.ncbi.nlm.nih.gov/pubmed/35887662 http://dx.doi.org/10.3390/jpm12071166

Ejemplares similares

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Innate immunity and nonalcoholic fatty liver disease
por: Kountouras, Jannis, et al.
Publicado: (2023)

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
por: Raptis, Dimitrios D, et al.
Publicado: (2023)

Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
por: Polyzos, Stergios A., et al.
Publicado: (2020)

Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Orfanidou, Myrsini, et al.
Publicado: (2023)

Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Combination therapies in nonalcoholic fatty liver disease using antidiabetic and disease-specific drugs
por: Koureta, Evgenia, et al.
Publicado: (2023)

Sirtuins and nonalcoholic fatty liver disease
por: Nassir, Fatiha, et al.
Publicado: (2016)

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Role of Mitochondria in Nonalcoholic Fatty Liver Disease
por: Nassir, Fatiha, et al.
Publicado: (2014)

Probiotics and Nonalcoholic Fatty liver Disease
por: Eslamparast, Tannaz, et al.
Publicado: (2013)

Dietary Anthocyanins as Nutritional Therapy for Nonalcoholic Fatty Liver Disease
por: Valenti, Luca, et al.
Publicado: (2013)

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
por: Li, Andrew A., et al.
Publicado: (2020)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease and non-liver comorbidities
por: Manikat, Richie, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

Autophagy: a new target for nonalcoholic fatty liver disease therapy
por: Mao, Yuqing, et al.
Publicado: (2016)

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
por: Ma, Junli, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy
por: Tarantino, Giovanni, et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
por: Di Ciaula, Agostino, et al.
Publicado: (2021)

The Role of Phytosterols in Nonalcoholic Fatty Liver Disease
por: Frasinariu, Otilia, et al.
Publicado: (2022)

MicroRNAs in Nonalcoholic Fatty Liver Disease
por: Baffy, György
Publicado: (2015)

Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease
por: Chen, Guanliang, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease: Evolving paradigms
por: Lonardo, Amedeo, et al.
Publicado: (2017)

Metabolic Targets in Nonalcoholic Fatty Liver Disease
por: Esler, William P., et al.
Publicado: (2019)

Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis
por: Pickett-Blakely, Octavia, et al.
Publicado: (2018)

Genetic predisposition in nonalcoholic fatty liver disease
por: Sookoian, Silvia, et al.
Publicado: (2017)

DNA Methylation in Nonalcoholic Fatty Liver Disease
por: Hyun, Jeongeun, et al.
Publicado: (2020)

Recent Epidemiology of Nonalcoholic Fatty Liver Disease
por: Murag, Soumya, et al.
Publicado: (2021)

Nutritional Genomics in Nonalcoholic Fatty Liver Disease
por: Vasconcellos, Carolina, et al.
Publicado: (2023)

Risk factors in nonalcoholic fatty liver disease
por: Ko, Eunji, et al.
Publicado: (2023)

Growth hormone and nonalcoholic fatty liver disease
por: Ma, Ingrid L., et al.
Publicado: (2023)

Role of bioactive fatty acids in nonalcoholic fatty liver disease
por: Juárez-Hernández, Eva, et al.
Publicado: (2016)

Nuclear Receptors in Nonalcoholic Fatty Liver Disease
por: López-Velázquez, Jorge A., et al.
Publicado: (2012)

Nonalcoholic Fatty Liver Disease after Liver Transplant
por: Shetty, Akshay, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease - A multisystem disease?
por: Mikolasevic, Ivana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_97b2p43hhpk7b3t5jbebng7dns